2017-07-06 |
1 |
|
Label (April 2017), # 2 Exhibit B: U.S. Patent No. 9,393,237, # 3 Exhibit C: Actavis ANDA Approved Labeling…2017
31 July 2022
2:17-cv-04964
835 Patent - Abbreviated New Drug Application(ANDA)
Plaintiff |
External link to document |
2017-07-08 |
10 |
|
U.S. Patent No. 9,393,237, # 4 Exhibit 3: U.S. Patent No. 8,658,663, # 5 Exhibit 4: U.S. Patent No. 8,946,251…2017
31 July 2022
2:17-cv-04964
835 Patent - Abbreviated New Drug Application(ANDA)
Plaintiff |
External link to document |
2017-07-10 |
11 |
|
HOLDER or l'ATENT OR TRADEMARK.
I us 9,393,237 7/19/2016 … ~
0 Trademarks or ~Patents. ( O the patent action involves 35 U.S.C. § 292.):
DOCKET…
AO120 Patent Form filed. (jr) (Entered: 07/10/2017)
10 July 2017
PACER Document
… REPORT ON THE
Director of the U.S. Patent and Trademark Office … ACTION REGARDING A PATENT OR
Alexandria, VA 22313 |
External link to document |
2017-07-20 |
22 |
|
and administered at 0.01, 1.0, 10, 30 60 mg/kg) or 1-[1-(3-chlorophenyl)-2-(4-methyl-
…fluoxetine (Sigma, dissolved in sterile H20 at 10, 30, 60 mg/kg) or
combination of fluoxetine ·administered…in sterile H2 0 and
administered at 1.0, 10, 30, 60 mg/kg) 1 hour prior to naloxone. Venlafaxine …dissolved in sterile H20 and administered at 1.0, 10, 30, 60 mg/kg), S-
enantiomer of .oov …dissolved in sterile H20 and administered at 1.0, 10, 30, 60 mg/kg), or
paroxetine (which was synthesized |
External link to document |
2017-07-25 |
26 |
|
U.S. Patent No. 5,955,475, # 3 Exhibit 35: U.S. Patent No. 6,113,944, # 4 Exhibit 36: U.S. Patent No. …6,645,523, # 5 Exhibit 37: U.S. Patent No. 6,660,298, # 6 Exhibit 38: U.S. Patent No. 6,699,882, # 7 Exhibit…40: U.S. Patent Application Publication No. 2004/0067254 (Lemmens), # 9 Exhibit 41: U.S. Patent No. 6,369,051…2017
31 July 2022
2:17-cv-04964
835 Patent - Abbreviated New Drug Application(ANDA)
Plaintiff |
External link to document |
2017-10-02 |
50 |
|
A: Brisdelle Label, # 2 Exhibit B: U.S. Patent No. 9,393,237, # 3 Exhibit C: Prinston ANDA Approval Letter…2017
31 July 2022
2:17-cv-04964
835 Patent - Abbreviated New Drug Application(ANDA)
Plaintiff |
External link to document |
2017-10-20 |
60 |
|
Case No. 17-4964
(the “‘447 patent”) and 7,598,271 (the “‘271 patent”), were also asserted in the Prior…this Court: U.S. Patent Nos. 8,658,663 (the “‘663 patent”) and 8,946,251 (the “‘251 patent”). All
three …237 patent is identical
to those of the ‘663 and ‘251 patents.
The ‘663 and ‘251 patents are… the ‘237 patent is
very similar to claim I of the ‘251 patent. Claim 1 of the ‘251 patent recites:
…would infringe the claims of
U.S. Patent No. 9,393,237 (the “‘237 patent”),’ For the reasons set forth below |
External link to document |